Evergreen Theragnostics, a pharmaceutical company engaged in the research and development of radiopharmaceuticals for the treatment of oncology, founded in 2019 in the US by James Cook, Enrico De Maria (pictured) and other Italian investors, including LIFTT and Club degli Investitori, and international investors will be fully acquired by US-based Lantheus Holdings, a radiopharmaceutical company committed to helping doctors detect, combat and monitor diseases to ensure better patient outcomes, with an initial payment of USD 250 million, to which milestone payments of up to USD 752.5 million could be added.
The objective of the acquisition is to transform Lantheus into a fully integrated radiopharmaceutical company.
The transaction offers significant strategic advantages, including Evergreen’s scalable manufacturing infrastructure, CDMO services and OCTEVY, a diagnostic agent in the registration phase for neuroendocrine tumours, which complements Lantheus’ therapeutic candidate PNT2003. The acquisition also strengthens Lantheus’ oncology portfolio, including several therapeutic and diagnostic pairs in clinical and pre-clinical phases.
The transaction is expected to be finalised in the second half of 2025, subject to the fulfilment of standard conditions.
Evergreen succeeded during the pandemic period in developing its plant, its first products, and quickly established itself as a leader in nuclear medicine. The deal will enable the company to accelerate the development of new oncology radiopharmaceuticals, expanding access to life-saving treatments for patients worldwide.
Members of the Club degli Investitori have believed in the initiative since the seed round in 2020 and reinvested increasing amounts in the following two rounds for a total of more than five million dollars. The transaction was overseen by the Club degli Investitori team and finalised with Simon Fiduciaria.
Enrico De Maria, co-founder of Evergreen Theragnostics, says in a note: ‘From the very beginning, we have believed in Evergreen Theragnostics’ ability to revolutionise cancer treatment through innovation in radiopharmaceuticals. This exit represents not only an extraordinary achievement for the company, but also a testament to the potential of companies funded by Investors Club Members to innovate and compete globally. I am immensely proud of Evergreen’s journey and grateful to the Investors’ Club for the support and trust that enabled us to reach this extraordinary milestone.”
Andrea Rota, managing director of the Club degli Investitori, comments: ‘The Investors’ Club today celebrates the success of our member Enrico de Maria and the entrepreneurial team that, under the leadership of James Cook, created Evergreen Theragnostic. Our partners believed in the project when it was just an idea, they saw the birth of a state-of-the-art plant, they continued to invest in all the rounds after their entry, and they supported increasingly ambitious research and development activities. Today we are happy to have helped James, Enrico and the entire Evergreen team to make a positive and indelible impact in an industry close to our hearts. Thank you and congratulations from all the members of the Club degli Investitori”.
Giovanni Tesoriere, CEO of LIFTT, which with the transaction achieves a return on investment of approximately 2.1 times the amount invested in less than a year, and up to seven times the milestones over the next few years, says: “This exit represents a significant achievement for LIFTT and underlines our commitment to supporting the development of new solutions for oncology patients and our dedication to an increasingly strategic sector for human health. Tesoriere is also co-founder of Evergreen Theragnostics.
“Today marks an exciting new chapter for Evergreen as we prepare to join the Lantheus team,” says James Cook, CEO of Evergreen. “Lantheus’ industry expertise and financial strength will help us bring our innovations to a broad patient population faster and support our mission to improve options for cancer patients through theranostic radiopharmaceuticals. We are excited to benefit from Lantheus’ experience and resources to further advance our pipeline and continue to develop cutting-edge therapies and diagnostics with the potential to transform patient care. I am very pleased that our team at Evergreen is joining another industry leader, sharing a common vision.”
ALL RIGHTS RESERVED ©